Ameriprise Financial Inc Ocugen, Inc. Transaction History

Ameriprise Financial Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.87 $99 - $168	-90 Reduced 0.25%	35,758 $46,000
Q3 2022 Nov 14, 2022	SELL	$1.75 - $3.1 $14,350 - $25,420	-8,200 Reduced 18.62%	35,848 $63,000
Q2 2022 Aug 15, 2022	SELL	$1.83 - $3.45 $10,275 - $19,371	-5,615 Reduced 11.31%	44,048 $100,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $4,001 - $8,071	-1,710 Reduced 3.33%	49,663 $164,000
Q4 2021 Feb 14, 2022	SELL	$4.38 - $15.67 $155,424 - $556,049	-35,485 Reduced 40.85%	51,373 $233,000
Q3 2021 Nov 15, 2021	BUY	$6.36 - $8.51 $33,708 - $45,103	5,300 Added 6.5%	86,858 $624,000
Q2 2021 Aug 16, 2021	BUY	$5.52 - $15.68 $313,536 - $890,624	56,800 Added 229.42%	81,558 $655,000
Q1 2021 May 17, 2021	BUY	$1.66 - $15.81 $41,098 - $391,423	24,758 New	24,758 $168,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.